Overview

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

Status:
Completed

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea and vomiting (CINV) in hematology patients receiving highly or moderately emetogenic chemotherapy regimens.

Phase:

Phase 3

Details

Lead Sponsor:

Augusta University

Collaborator:

University of Georgia

Treatments:

Aprepitant
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Emetics
Fosaprepitant
Olanzapine
Ondansetron